Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LINDA M PAO

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1417973827
CMS profile
245322
Location
JUPITER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,952.10

132 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,952.10 132

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LINDA M PAO

NPI 1417973827 · CMS profile ID 245322

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

JUPITER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417973827?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LINDA M PAO, NPI 1417973827, CMS profile ID 245322. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417973827?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). LINDA M PAO, NPI 1417973827, CMS profile ID 245322. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417973827?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
LINDA M PAO, NPI 1417973827, CMS profile ID 245322, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1417973827?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

132 matching records · $2,952.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 132 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 132.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $22.5206/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954575879 CMS
Biogen, Inc. $22.0106/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923429461 CMS
EMD Serono, Inc. $80.8306/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941532079 CMS
Amneal Pharmaceuticals LLC $17.8106/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956592911 CMS
Alexion Pharmaceuticals, Inc. $16.9606/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915685405 CMS
Teva Pharmaceuticals USA, Inc. $4.8306/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954575767 CMS
Teva Pharmaceuticals USA, Inc. $10.0206/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954575961 CMS
GENZYME CORPORATION $18.2006/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938811261 CMS
ABBVIE INC. $16.9906/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891311269 CMS
Sunovion Pharmaceuticals Inc. $21.3506/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920976593 CMS
Novartis Pharmaceuticals Corporation $21.9906/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894198689 CMS
Neurocrine Biosciences, Inc. $19.1606/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963347449 CMS
Amneal Pharmaceuticals LLC $18.8905/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956592907 CMS
Novartis Pharmaceuticals Corporation $20.9405/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894198693 CMS
Novartis Pharmaceuticals Corporation $5.8305/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894198685 CMS
EISAI INC. $20.2705/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908057807 CMS
Lilly USA, LLC $18.3305/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918178909 CMS
EMD Serono, Inc. $31.5105/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941514625 CMS
Janssen Pharmaceuticals, Inc $17.0805/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885946547 CMS
Teva Pharmaceuticals USA, Inc. $21.2905/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954575725 CMS
GENZYME CORPORATION $21.4305/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938811253 CMS
Acorda Therapeutics, Inc $18.9705/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920335665 CMS
Alexion Pharmaceuticals, Inc. $16.6105/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915550631 CMS
Celgene Corporation $24.4905/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932528913 CMS
Neurelis, Inc. $16.4505/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950156027 CMS
Novartis Pharmaceuticals Corporation $24.7605/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894198677 CMS
Teva Pharmaceuticals USA, Inc. $6.2705/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954575665 CMS
Teva Pharmaceuticals USA, Inc. $7.0105/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954575671 CMS
Celgene Corporation $15.4304/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932528911 CMS
Sunovion Pharmaceuticals Inc. $18.4604/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921005113 CMS
Novartis Pharmaceuticals Corporation $18.8304/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894198681 CMS
Lilly USA, LLC $20.2304/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918133577 CMS
Genentech USA, Inc. $1.8804/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950785571 CMS
Genentech USA, Inc. $23.4404/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950785573 CMS
EMD Serono, Inc. $34.8804/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941505211 CMS
MITSUBISHI TANABE PHARMA AMERICA, INC. $23.0504/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940567675 CMS
Teva Pharmaceuticals USA, Inc. $5.7704/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954575833 CMS
ITF Pharma, Inc. $72.8304/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962018597 CMS
Neurelis, Inc. $20.4704/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950156025 CMS
Biogen, Inc. $14.2904/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923457677 CMS
Novartis Pharmaceuticals Corporation $22.7604/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894198673 CMS
Biohaven Pharmaceutical Holding Company Ltd. $22.8703/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923694411 CMS
ACADIA Pharmaceuticals Inc $14.6403/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952391245 CMS
GENZYME CORPORATION $124.9903/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938811245 CMS
ABBVIE INC. $20.4303/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891311267 CMS
Neurocrine Biosciences, Inc. $17.2403/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963347445 CMS
Teva Pharmaceuticals USA, Inc. $5.1603/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954575653 CMS
Teva Pharmaceuticals USA, Inc. $24.0703/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954575659 CMS
GENZYME CORPORATION $15.7203/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938811243 CMS
Novartis Pharmaceuticals Corporation $20.2203/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894198615 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,280.99 219
PY2020 $2,233.01 122
PY2021 $3,591.88 194
PY2022 $2,952.10 132
PY2023 $3,810.37 10
PY2024 $2,271.52 21
PY2025 $19,099.68 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,479,839.35 120
PY2024 Principal investigator $610,719.26 31
PY2023 Recipient $153.00 1
PY2023 Principal investigator $16,044.94 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

120 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $6,979.00 12/29/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420482
Principal investigator 1 Janssen Research & Development, LLC $9,688.00 12/22/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420303
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 12/12/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420563
Principal investigator 1 Janssen Research & Development, LLC $7,890.00 12/12/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420617
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 11/25/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192104537
Principal investigator 1 GlaxoSmithKline, LLC. $2,025.00 11/25/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192159348
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 11/25/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192161730
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 11/25/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192161739
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 11/06/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192161747
Principal investigator 1 Novartis Pharmaceuticals Corporation $114.00 10/28/2025 Non-covered Recipient Entity
JEM RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-controlled Parallel Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks Followed by an Open Label Extension (ASTRALS) No dispute reported 06/30/2026 1190301407
Principal investigator 1 GlaxoSmithKline, LLC. $5,675.00 10/24/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192103067
Principal investigator 1 GlaxoSmithKline, LLC. $7,170.70 10/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192161743
Principal investigator 1 Janssen Research & Development, LLC $4,079.00 09/29/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420158
Principal investigator 1 Janssen Research & Development, LLC $6,140.00 09/29/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420172
Principal investigator 1 Janssen Research & Development, LLC $300.00 09/29/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420225
Principal investigator 1 Janssen Research & Development, LLC $500.00 09/29/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420254
Principal investigator 1 Janssen Research & Development, LLC $800.00 09/29/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420298
Principal investigator 1 Janssen Research & Development, LLC $15,780.00 09/29/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420348
Principal investigator 1 Janssen Research & Development, LLC $56,656.00 09/29/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420430
Principal investigator 1 GlaxoSmithKline, LLC. $2,467.80 09/15/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192161609
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $65,464.92 09/08/2025 Non-covered Recipient Entity
Jem Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) No dispute reported 06/30/2026 1235996481
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 08/28/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192103061
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,705.02 08/26/2025 Non-covered Recipient Entity
Jem Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) No dispute reported 06/30/2026 1235996475
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 08/22/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192159357
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 08/22/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192161726
Principal investigator 1 GlaxoSmithKline, LLC. $2,467.80 08/13/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192159326
Principal investigator 1 Janssen Research & Development, LLC $2,160.00 08/11/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420099
Principal investigator 1 Janssen Research & Development, LLC $1,440.00 08/11/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420383
Principal investigator 1 Janssen Research & Development, LLC $1,265.00 08/11/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420476
Principal investigator 1 Janssen Research & Development, LLC $4,749.00 08/11/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420488
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 07/31/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192103041
Principal investigator 1 GlaxoSmithKline, LLC. $6,821.05 07/21/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192161615
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,446.61 07/14/2025 Non-covered Recipient Entity
Jem Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) No dispute reported 06/30/2026 1235996483
Principal investigator 1 Janssen Research & Development, LLC $5,406.00 07/11/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420258
Principal investigator 1 Janssen Research & Development, LLC $4,079.00 07/11/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420512
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 07/10/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192103087
Principal investigator 1 Novartis Pharmaceuticals Corporation $234.01 07/08/2025 Non-covered Recipient Entity
JEM RESEARCH INSTITUTE
"A Phase 2, Randomized, Double-blind, Placebo-controlled Parallel Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks Followed by an Open Label Extension (ASTRALS)" No dispute reported 06/30/2026 1190301409
Principal investigator 1 GlaxoSmithKline, LLC. $81.00 06/25/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192161751
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 06/23/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192103048
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 06/23/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192159322
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 06/23/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192159336
Principal investigator 1 GlaxoSmithKline, LLC. $783.00 06/23/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192159344
Principal investigator 1 Janssen Research & Development, LLC $3,945.00 06/16/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420109
Principal investigator 1 Janssen Research & Development, LLC $12,237.00 06/16/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420238
Principal investigator 1 Janssen Research & Development, LLC $1,440.00 06/16/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420246
Principal investigator 1 Janssen Research & Development, LLC $720.00 06/16/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420314
Principal investigator 1 Janssen Research & Development, LLC $720.00 06/16/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420329
Principal investigator 1 Janssen Research & Development, LLC $12,280.00 06/16/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420600
Principal investigator 1 Janssen Research & Development, LLC $11,835.00 06/16/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420628
Principal investigator 1 Janssen Research & Development, LLC $146.00 06/12/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420080
Principal investigator 1 Janssen Research & Development, LLC $750.00 06/12/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420215
Principal investigator 1 Janssen Research & Development, LLC $146.00 06/12/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420336
Principal investigator 1 GlaxoSmithKline, LLC. $4,251.83 05/15/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192103054
Principal investigator 1 Janssen Research & Development, LLC $13,836.00 05/12/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420453
Principal investigator 1 Avid Radiopharmaceuticals, Inc. $103,803.35 05/01/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
CUTANEOUS ALPHA-SYNUCLEIN EVALUATION IN DONANEMAB-TREATED PATIENTS No dispute reported 06/30/2026 1187885218
Principal investigator 1 GlaxoSmithKline, LLC. $70.00 04/28/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192104514
Principal investigator 1 GlaxoSmithKline, LLC. $54.00 04/28/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192104519
Principal investigator 1 Janssen Research & Development, LLC $23,670.00 04/21/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420363
Principal investigator 1 Janssen Research & Development, LLC $3,945.00 04/21/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420470
Principal investigator 1 Janssen Research & Development, LLC $15,780.00 04/21/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420505
Principal investigator 1 Janssen Research & Development, LLC $130,800.00 04/14/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420547
Principal investigator 1 GlaxoSmithKline, LLC. $8,006.18 04/09/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192103074
Principal investigator 1 GlaxoSmithKline, LLC. $54.00 04/01/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192159340
Principal investigator 1 GlaxoSmithKline, LLC. $70.00 04/01/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192161755
Principal investigator 1 Janssen Research & Development, LLC $43,980.00 03/24/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420309
Principal investigator 1 GlaxoSmithKline, LLC. $14,981.13 02/27/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192103080
Principal investigator 1 GlaxoSmithKline, LLC. $2,227.50 02/27/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192104526
Principal investigator 1 GlaxoSmithKline, LLC. $864.34 02/27/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192104531
Principal investigator 1 GlaxoSmithKline, LLC. $2,700.00 02/27/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192104542
Principal investigator 1 GlaxoSmithKline, LLC. $2,700.00 02/27/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192159331
Principal investigator 1 GlaxoSmithKline, LLC. $6,750.00 02/27/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192159352
Principal investigator 1 GlaxoSmithKline, LLC. $7,284.60 02/27/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192161735
Principal investigator 1 Janssen Research & Development, LLC $12,237.00 02/24/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420231
Principal investigator 1 Janssen Research & Development, LLC $10,080.00 02/24/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420377
Principal investigator 1 Janssen Research & Development, LLC $8,640.00 02/24/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420389
Principal investigator 1 Janssen Research & Development, LLC $15,780.00 02/24/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420408
Principal investigator 1 Janssen Research & Development, LLC $2,160.00 02/24/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420417
Principal investigator 1 Janssen Research & Development, LLC $18,420.00 02/24/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420524
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 02/24/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420611
Principal investigator 1 Janssen Research & Development, LLC $720.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420115
Principal investigator 1 Janssen Research & Development, LLC $912.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420120
Principal investigator 1 Janssen Research & Development, LLC $53.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420140
Principal investigator 1 Janssen Research & Development, LLC $8,640.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420188
Principal investigator 1 Janssen Research & Development, LLC $5,760.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420193
Principal investigator 1 Janssen Research & Development, LLC $2,394.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420289
Principal investigator 1 Janssen Research & Development, LLC $4,320.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420321
Principal investigator 1 Janssen Research & Development, LLC $7,200.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420369
Principal investigator 1 Janssen Research & Development, LLC $720.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420403
Principal investigator 1 Janssen Research & Development, LLC $1,440.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420424
Principal investigator 1 Janssen Research & Development, LLC $912.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420492
Principal investigator 1 Janssen Research & Development, LLC $5,760.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420498
Principal investigator 1 Janssen Research & Development, LLC $3,600.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420517
Principal investigator 1 Janssen Research & Development, LLC $114.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420559
Principal investigator 1 Janssen Research & Development, LLC $36,624.00 02/17/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420634
Principal investigator 1 Eli Lilly and Company $195.00 01/31/2025 Non-covered Recipient Entity
JEM RESEARCH LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883014
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,015.33 01/27/2025 Non-covered Recipient Entity
Jem Research Institute
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235996479
Principal investigator 1 Eli Lilly and Company $18,094.91 01/27/2025 Non-covered Recipient Entity
JEM RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187885222
Principal investigator 1 Janssen Research & Development, LLC $34,008.00 01/23/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420087
Principal investigator 1 Janssen Research & Development, LLC $2,622.00 01/23/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420130
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 01/23/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420180
Principal investigator 1 Janssen Research & Development, LLC $114.00 01/23/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420209
Principal investigator 1 Janssen Research & Development, LLC $1,026.00 01/23/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420221
Principal investigator 1 Janssen Research & Development, LLC $897.00 01/23/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420273
Principal investigator 1 Janssen Research & Development, LLC $798.00 01/23/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420448
Principal investigator 1 Janssen Research & Development, LLC $13,080.00 01/23/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420582
Principal investigator 1 Eli Lilly and Company $344,634.65 01/22/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883774
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $382,485.62 01/21/2025 Non-covered Recipient Entity
Jem Research Institute
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235996477
Principal investigator 1 Janssen Research & Development, LLC $15,780.00 01/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420105
Principal investigator 1 Janssen Research & Development, LLC $19,725.00 01/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420135
Principal investigator 1 Janssen Research & Development, LLC $570.00 01/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420151
Principal investigator 1 Janssen Research & Development, LLC $12,280.00 01/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420165
Principal investigator 1 Janssen Research & Development, LLC $12,540.00 01/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420199
Principal investigator 1 Janssen Research & Development, LLC $1,026.00 01/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420279
Principal investigator 1 Janssen Research & Development, LLC $2,736.00 01/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420352
Principal investigator 1 Janssen Research & Development, LLC $1,596.00 01/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420464
Principal investigator 1 Janssen Research & Development, LLC $1,026.00 01/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420541
Principal investigator 1 Janssen Research & Development, LLC $8,158.00 01/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420553
Principal investigator 1 Janssen Research & Development, LLC $1,824.00 01/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420569
Principal investigator 1 Janssen Research & Development, LLC $5,700.00 01/20/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175420587
Principal investigator 1 Eli Lilly and Company $777,503.00 01/13/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187883010